Clinical Trial Update: Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001 [Phase 2]

View source ↗

Summary

Phase 2 trial update of EXC 001 assessing safety and efficacy in participants from prior studies; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Reduction in Severity of Skin Scarring
• Scar Assessment

Drugs mentioned

• EXC 001

Snippet

Sponsor: Pfizer | Conditions: Reduction in Severity of Skin Scarring | Phase 2 | Status: COMPLETED | Results posted: 2021-08-13